Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer.
Bartolomeo V, Cortiula F, Hendriks LEL, De Ruysscher D, Filippi AR. Bartolomeo V, et al. Among authors: filippi ar. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1455-1460. doi: 10.1016/j.ijrobp.2023.11.005. Epub 2023 Dec 27. Int J Radiat Oncol Biol Phys. 2024. PMID: 38159097 No abstract available.
Editorial: Imaging assessment of response to immunotherapy.
Occhipinti M, Filippi AR, Walsh S, van Meerbeeck JP. Occhipinti M, et al. Among authors: filippi ar. Front Oncol. 2023 Jan 20;12:1116315. doi: 10.3389/fonc.2022.1116315. eCollection 2022. Front Oncol. 2023. PMID: 36741725 Free PMC article. No abstract available.
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
Catania C, Filippi AR, Sangalli C, Piperno G, Russano M, Greco C, Scotti V, Proto C, Bennati C, Di Pietro Paolo M, Platania A, Olmetto E, Agustoni F, Teodorani N, Agbaje V, Russo A. Catania C, et al. Among authors: filippi ar. Crit Rev Oncol Hematol. 2023 Oct;190:104108. doi: 10.1016/j.critrevonc.2023.104108. Epub 2023 Aug 24. Crit Rev Oncol Hematol. 2023. PMID: 37633350 Review.
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Girard N, et al. Among authors: filippi ar. J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub 2022 Oct 25. J Thorac Oncol. 2023. PMID: 36307040 Free article.
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC.
Reck M, Nadal E, Girard N, Filippi AR, Martin LW, Gay CM, Petersen C, Gale D, Emeribe UA, Georgoulia N, Perez IED, Spicer JD. Reck M, et al. Among authors: filippi ar. Clin Lung Cancer. 2024 Sep;25(6):587-593.e3. doi: 10.1016/j.cllc.2024.06.007. Epub 2024 Jun 21. Clin Lung Cancer. 2024. PMID: 39003185 Free article.
CT and MRI radiomic features of lung cancer (NSCLC): comparison and software consistency.
Bortolotto C, Pinto A, Brero F, Messana G, Cabini RF, Postuma I, Robustelli Test A, Stella GM, Galli G, Mariani M, Figini S, Lascialfari A, Filippi AR, Bottinelli OM, Preda L. Bortolotto C, et al. Among authors: filippi ar. Eur Radiol Exp. 2024 Jun 17;8(1):71. doi: 10.1186/s41747-024-00468-8. Eur Radiol Exp. 2024. PMID: 38880866 Free PMC article.
172 results